ZA201104911B - Inhibitors of hcv ns5a - Google Patents

Inhibitors of hcv ns5a

Info

Publication number
ZA201104911B
ZA201104911B ZA2011/04911A ZA201104911A ZA201104911B ZA 201104911 B ZA201104911 B ZA 201104911B ZA 2011/04911 A ZA2011/04911 A ZA 2011/04911A ZA 201104911 A ZA201104911 A ZA 201104911A ZA 201104911 B ZA201104911 B ZA 201104911B
Authority
ZA
South Africa
Prior art keywords
inhibitors
hcv ns5a
ns5a
hcv
Prior art date
Application number
ZA2011/04911A
Other languages
English (en)
Inventor
Leping Li
Min Zhong
Original Assignee
Presidio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42233598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201104911(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Presidio Pharmaceuticals Inc filed Critical Presidio Pharmaceuticals Inc
Publication of ZA201104911B publication Critical patent/ZA201104911B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA2011/04911A 2008-12-03 2011-06-30 Inhibitors of hcv ns5a ZA201104911B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11972308P 2008-12-03 2008-12-03
US17359009P 2009-04-28 2009-04-28
US18295209P 2009-06-01 2009-06-01
PCT/US2009/066451 WO2010065668A1 (en) 2008-12-03 2009-12-02 Inhibitors of hcv ns5a

Publications (1)

Publication Number Publication Date
ZA201104911B true ZA201104911B (en) 2012-03-28

Family

ID=42233598

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/04911A ZA201104911B (en) 2008-12-03 2011-06-30 Inhibitors of hcv ns5a

Country Status (20)

Country Link
US (3) US9120779B2 (enExample)
EP (3) EP2373168A4 (enExample)
JP (2) JP2012510523A (enExample)
KR (1) KR20110098779A (enExample)
CN (2) CN102300462B (enExample)
AR (2) AR074474A1 (enExample)
AU (2) AU2009322400A1 (enExample)
BR (1) BRPI0922364A2 (enExample)
CA (2) CA2750577A1 (enExample)
CL (1) CL2011001332A1 (enExample)
CO (1) CO6390076A2 (enExample)
EA (1) EA201190007A1 (enExample)
IL (2) IL213278A0 (enExample)
MX (1) MX2011005896A (enExample)
NZ (2) NZ593806A (enExample)
PE (1) PE20120207A1 (enExample)
SG (2) SG171890A1 (enExample)
TW (2) TWI472526B (enExample)
WO (2) WO2010065668A1 (enExample)
ZA (1) ZA201104911B (enExample)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
AU2009322393B2 (en) * 2008-12-03 2017-02-02 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
WO2010075376A2 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
SG172353A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
JP5628841B2 (ja) * 2009-02-27 2014-11-19 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビター
US8673954B2 (en) * 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
AU2013204195B2 (en) * 2009-02-27 2016-09-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8507522B2 (en) * 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
TWI476190B (zh) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102459165B (zh) * 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
WO2010132538A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
EA037281B1 (ru) * 2009-05-13 2021-03-04 Джилид Фармассет Ллс Способы получения противовирусного соединения
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8980920B2 (en) * 2009-05-29 2015-03-17 Merck Sharp & Dohme Corp. Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C
AU2010253790A1 (en) 2009-05-29 2011-12-15 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5530514B2 (ja) 2009-06-11 2014-06-25 アッヴィ・バハマズ・リミテッド Ｈｃｖ感染を治療するための抗ウィルス化合物
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
IN2012DN00999A (enExample) 2009-07-16 2015-04-10 Vertex Pharma
AU2010276441B2 (en) 2009-07-21 2015-07-02 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
CA2768638A1 (en) * 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Bis-benzimidazole derivatives as hepatitis c virus inhibitors
WO2011015657A1 (en) 2009-08-07 2011-02-10 Tibotec Pharmaceuticals Phenyl ethynyl derivatives as hepatitis c virus inhibitors
US20120172368A1 (en) 2009-09-03 2012-07-05 Koen Vandyck Bis-Benzimidazole Derivatives
EA201290089A1 (ru) 2009-09-04 2012-09-28 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Химические соединения
KR20120081123A (ko) 2009-09-09 2012-07-18 길리애드 사이언시즈, 인코포레이티드 플라비비리대 바이러스의 억제제
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475254A4 (en) * 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102791687B (zh) * 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
SG181614A1 (en) * 2009-12-24 2012-07-30 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011088303A1 (en) 2010-01-15 2011-07-21 Gilead Sciences , Inc. Inhibitors of flaviviridae viruses
SI2523950T1 (sl) 2010-01-15 2017-06-30 Gilead Sciences, Inc. Inhibitorji flaviviridae virusov
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011091417A1 (en) 2010-01-25 2011-07-28 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
EP2542074A4 (en) * 2010-03-04 2014-05-14 Enanta Pharm Inc PHARMACEUTICAL COMBINATION ACTIVE AGENTS AS HCV REPLICATION INHIBITORS
AR080676A1 (es) 2010-03-09 2012-05-02 Schering Corp Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
EP2550268A1 (en) * 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
US20130296311A1 (en) * 2010-05-28 2013-11-07 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
TW201201801A (en) * 2010-06-09 2012-01-16 Presidio Pharmaceuticals Inc Inhibitors of HCV NS5A protein
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
MX2012014918A (es) 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
EP2598498B1 (en) 2010-07-26 2014-07-09 Janssen R&D Ireland Hetero-bicyclic derivatives as hcv inhibitors
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
AU2010358561B2 (en) * 2010-08-04 2016-06-02 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012021704A1 (en) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2012024363A2 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
EP2963034A1 (en) 2010-08-26 2016-01-06 RFS Pharma, LLC. Potent and selective inhibitors of hepatitis c virus
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
JP5619289B2 (ja) * 2010-09-24 2014-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CN103459399A (zh) * 2010-09-29 2013-12-18 默沙东公司 用于治疗丙型肝炎病毒感染的四环吲哚衍生物
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
KR20140001879A (ko) * 2010-09-29 2014-01-07 머크 샤프 앤드 돔 코포레이션 Ｃ형 간염 바이러스 감염을 치료하기 위한 테트라시클릭 인돌 유도체
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
SI2692346T1 (sl) * 2010-10-13 2016-03-31 Abbvie Bahamas Limited Antivirusni derivati 1-fenil-2,5-dibenzimidazol-5-il-pirolidina
AU2014203655B2 (en) * 2010-10-13 2016-07-07 Abbvie Ireland Unlimited Company Anti-viral compounds
WO2012058125A1 (en) 2010-10-26 2012-05-03 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
US8921372B2 (en) 2010-11-04 2014-12-30 Theravance Biopharma R&D Ip, Llc Inhibitors of hepatitis C virus
CA3102625C (en) 2010-11-17 2024-02-20 Gilead Pharmasset Llc Antiviral compounds
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
WO2012083061A2 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
WO2012083048A2 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
WO2012083043A1 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
US20140343286A1 (en) * 2010-12-15 2014-11-20 Allan C. Krueger Anti-viral compounds
JP5906253B2 (ja) * 2010-12-16 2016-04-20 アッヴィ・インコーポレイテッド 抗ウイルス性化合物
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2012091115A1 (ja) * 2010-12-29 2012-07-05 キッセイ薬品工業株式会社 アセチレン誘導体及びその医薬用途
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103687489A (zh) 2011-05-18 2014-03-26 埃南塔制药公司 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
PT2734515E (pt) 2011-07-13 2016-03-11 Gilead Sciences Inc Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae
AR087346A1 (es) 2011-07-26 2014-03-19 Vertex Pharma Formulaciones de compuestos de tiofeno
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
UA110354C2 (uk) 2011-11-16 2015-12-25 Гайлід Фармассет Елелсі Противірусні сполуки
ES2564906T3 (es) * 2011-12-16 2016-03-29 F. Hoffmann-La Roche Ag Inhibidores de NS5A del VHC
US9126986B2 (en) 2011-12-28 2015-09-08 Janssen Sciences Ireland Uc Hetero-bicyclic derivatives as HCV inhibitors
RU2014131017A (ru) 2011-12-28 2016-02-20 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Хиназолиноновые производные в качестве ингибиторов hcv
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
IN2014MN01547A (enExample) * 2012-02-10 2015-05-08 Lupin Ltd
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
KR101693179B1 (ko) 2012-04-17 2017-01-05 후지필름 가부시키가이샤 함질소 복소환 화합물 또는 그 염
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
CN103848818B (zh) 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
TWI585082B (zh) 2012-11-29 2017-06-01 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們的用途
CN103880823B (zh) * 2012-12-21 2017-12-05 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物及其在药物中的应用
KR20140119012A (ko) 2013-01-31 2014-10-08 길리어드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
RU2507201C1 (ru) 2013-02-07 2014-02-20 Александр Васильевич Иващенко Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
US20150064253A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2015089810A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
CN103664581B (zh) * 2013-12-20 2016-07-06 中节能万润股份有限公司 一种反，反-4,4’-二环己基二甲酸的制备方法
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US9738629B2 (en) 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
MX387720B (es) 2014-04-15 2025-03-12 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de conductancia de transmembrana de fibrosis quística.
CN105175408B (zh) * 2014-06-04 2018-07-17 中国人民解放军第二军医大学 苯并噻唑类化合物及其作为药物的用途
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN106279117A (zh) * 2016-08-16 2017-01-04 上海同昌生物医药科技有限公司 一种雷迪帕韦中间体的合成方法及其产品
CN108727345B (zh) * 2017-04-25 2023-06-27 广东东阳光药业有限公司 一种咪唑环中间体的制备方法
JP7584418B2 (ja) 2018-12-04 2024-11-15 ブリストル－マイヤーズ スクイブ カンパニー 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021236771A1 (en) 2020-05-22 2021-11-25 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
US12264149B2 (en) 2020-12-30 2025-04-01 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
CN117321059A (zh) 2021-05-21 2023-12-29 吉利德科学公司 用于治疗寨卡病毒感染的四环化合物
CA3220903A1 (en) 2021-05-21 2022-11-24 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
EP4334298A1 (en) 2021-06-14 2024-03-13 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1244507B (it) * 1991-04-11 1994-07-15 Sigma Tau Ind Farmaceuti Derivati dell'acido piroglutammico quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
JPH09227417A (ja) * 1996-02-26 1997-09-02 Dainippon Ink & Chem Inc アルケニルトラン誘導体とその製造方法
IL126674A (en) 1996-04-23 2005-08-31 Vertex Pharma Use of cyclic and heterocyclic compounds for preparing pharmaceutical compositions inhibiting impdh activity, pharmaceutical compositions containing the same and novel thiazole and oxazole urea derivatives
JP3865084B2 (ja) * 1996-07-04 2007-01-10 大日本インキ化学工業株式会社 ジアルケニルトラン誘導体
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼの阻害因子
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
ES2244204T3 (es) 1998-07-27 2005-12-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Derivados de dicetoacidos como inhibidores de polimerasas.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
BR9913157A (pt) 1998-08-21 2001-05-15 Viropharma Inc Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
CA2343522A1 (en) 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
AU751457B2 (en) 1998-09-25 2002-08-15 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
AP1498A (en) 1999-03-19 2005-11-21 Vertex Pharma Inhibitors of impdh enzyme.
AU2935200A (en) * 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
EP1225899A2 (en) 1999-11-04 2002-07-31 Virochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
JP2001294541A (ja) * 2000-04-14 2001-10-23 Dainippon Ink & Chem Inc トラン誘導体の製造方法
AU2001261377A1 (en) 2000-05-10 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
JP4544857B2 (ja) 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の治療または予防のための化合物および方法
EP1395571A1 (en) 2001-06-11 2004-03-10 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007959A1 (en) * 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1440069B1 (en) 2001-11-02 2007-08-15 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
WO2003037894A1 (en) 2001-11-02 2003-05-08 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
EP1440068A1 (en) 2001-11-02 2004-07-28 Glaxo Group Limited Acyl dihydro pyrrole derivatives as hcv inhibitors
PL377215A1 (pl) 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
JP4206382B2 (ja) * 2002-11-19 2009-01-07 アキリオン ファーマシューティカルズ，インコーポレーテッド 置換されたアリールチオウレアおよび関連化合物；ウイルス複製のインヒビター
EP1572112A4 (en) * 2002-11-22 2006-12-06 Bristol Myers Squibb Co 3- (PYRIDINYL-PIPERAZINE-1-YL) -PHENYLETHYL AMIDES AS POTASIC CHANNEL OPENING AGENTS
AU2004235848B2 (en) * 2003-05-09 2011-08-04 Boehringer Ingelheim International Gmbh Hepatitis C virus NS5B polymerase inhibitor binding pocket
WO2005007648A2 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
PT1713823E (pt) 2004-01-30 2010-02-02 Medivir Ab Inibidores da protease ns-3 da serina do hcv
CA2573185A1 (en) * 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
ZA200701235B (en) * 2004-07-14 2009-10-28 Ptc Therapeutics Inc Methods for treating hepatitis C
US8143288B2 (en) * 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
JP5230414B2 (ja) * 2005-07-29 2013-07-10 テイボテク・フアーマシユーチカルズ Ｃ型肝炎ウイルスの大環状阻害剤
TW200813015A (en) 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2007321677B2 (en) * 2006-11-15 2013-04-11 Vertex Pharmaceuticals (Canada) Incorporated Thiophene analogues for the treatment or prevention of flavivirus infections
WO2008073461A2 (en) * 2006-12-11 2008-06-19 Wyeth Ion channel modulators
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
CN101280196B (zh) * 2008-06-03 2011-01-26 西安近代化学研究所 四环液晶化合物
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) * 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009322393B2 (en) * 2008-12-03 2017-02-02 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
JP5628841B2 (ja) 2009-02-27 2014-11-19 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビター
EA037281B1 (ru) * 2009-05-13 2021-03-04 Джилид Фармассет Ллс Способы получения противовирусного соединения

Also Published As

Publication number Publication date
CO6390076A2 (es) 2012-02-29
EP2373167A4 (en) 2012-07-25
CN102300461A (zh) 2011-12-28
US20110237579A1 (en) 2011-09-29
US20150038501A1 (en) 2015-02-05
EA201190007A1 (ru) 2012-06-29
MX2011005896A (es) 2011-09-29
NZ593806A (en) 2014-04-30
AU2009322387A1 (en) 2011-06-30
TW201033196A (en) 2010-09-16
EP2373167A1 (en) 2011-10-12
AR074474A1 (es) 2011-01-19
TW201031654A (en) 2010-09-01
EP2774927A1 (en) 2014-09-10
EP2373168A1 (en) 2011-10-12
TWI472526B (zh) 2015-02-11
CA2750577A1 (en) 2010-06-10
WO2010065668A1 (en) 2010-06-10
CN102300462B (zh) 2015-01-28
PE20120207A1 (es) 2012-03-31
JP2012510525A (ja) 2012-05-10
SG171890A1 (en) 2011-07-28
CA2745119A1 (en) 2010-06-10
JP2012510523A (ja) 2012-05-10
CL2011001332A1 (es) 2011-11-11
SG171891A1 (en) 2011-07-28
US9120779B2 (en) 2015-09-01
BRPI0922364A2 (pt) 2017-08-29
CN102300461B (zh) 2015-04-22
KR20110098779A (ko) 2011-09-01
IL213279A0 (en) 2011-07-31
NZ593808A (en) 2014-04-30
IL213278A0 (en) 2011-07-31
WO2010065681A1 (en) 2010-06-10
US8865756B2 (en) 2014-10-21
TWI494309B (zh) 2015-08-01
EP2373168A4 (en) 2012-08-01
AR080264A1 (es) 2012-03-28
AU2009322400A1 (en) 2011-06-30
US20120115855A1 (en) 2012-05-10
CN102300462A (zh) 2011-12-28

Similar Documents

Publication Publication Date Title
IL233818A0 (en) Inhibitors to ns5a hcv
IL213279A0 (en) Inhibitors of hcv ns5a
EP2398474A4 (en) HCV NS5A SHEMMER
EP2575866A4 (en) HCV NS5A INHIBITORS
EP2575475A4 (en) HCV NS5A INHIBITORS
SMT201600291B (it) Inibitori di proteasi hcv
AP3409A (en) Inhibitors of flaviviridae viruses
ZA201008988B (en) Hcv protease inhibitors
EP2410841A4 (en) SUBSTITUTED BICYCLIC HCV INHIBITORS
EP2271345A4 (en) HCV NS3 proteinase inhibitor
CY2017005I2 (el) Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
BRPI0923184A2 (pt) inibidores de hcv ns3 protease
ATE501156T1 (de) Cyclopropyl-annelierte indolobenzazepine als hcv- ns5b-inhibitoren
IL207459A0 (en) Hepatitis c virus inhibitors
IL207470A0 (en) Hepatitis c virus inhibitors
EP2618665A4 (en) HCV NS3 proteinase inhibitor
ZA201006719B (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
IL224178A (en) Heterogeneous history of cervix as hcv inhibitors
EP2432318A4 (en) NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
EP2364159A4 (en) DETERIORIC MACROCYCLIC INHIBITORS OF NS3 VIRAL PROTEASE
IL225908A0 (en) New specific inhibitors for 3ns hcv protease
TH0901005440A (th) ตัวยับยั้งของ hcv ns5a
HK1134509A (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
SG2014011258A (en) Hcv protease inhibitors
GB0803895D0 (en) Inhibitors of glyoxalase